Mammographic and clinical characteristics of different phenotypes of screen-detected and interval breast cancers in a nationwide screening program

被引：0

作者：

Marisa Baré

Núria Torà

Dolores Salas

Melchor Sentís

Joana Ferrer

Josefa Ibáñez

Raquel Zubizarreta

Garbiñe Sarriugarte

Teresa Barata

Laia Domingo

Xavier Castells

Maria Sala

机构：

[1] UDIAT-DC,Clinical Epidemiology and Cancer Screening

[2] Corporació Sanitària Parc Taulí,Department of Pediatrics, Obstetrics and Gynecology, and Preventive Medicine and Public Health, Faculty of Medicine

[3] Autonomous University of Barcelona (UAB),General Directorate Public Health and Centre for Public Health Research (CSISP)

[4] Research Network on Health Services in Chronic Diseases (REDISSEC),Breast Imaging, Department of Radiology

[5] FISABIO,Department of Radiology

[6] UDIAT-DC,Galician Breast Cancer Screening Programme

[7] Parc Taulí Sabadell,Osakidetza Breast Cancer Screening Programme

[8] Hospital de Santa Caterina,General Directorate of Health Care Programmes

[9] Directorate for Innovation and Management of Public Health,Department of Epidemiology and Evaluation

[10] Basque Country Health Service,undefined

[11] Canary Islands Health Service,undefined

[12] IMIM (Hospital del Mar Medical Research Institute),undefined

来源：

Breast Cancer Research and Treatment | 2015年 / 154卷

关键词：

Breast cancer; HER2+; Triple-negative; Mammographic features; Screening; Interval cancer;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

In the context of a population-based screening program, we aimed to evaluate the major mammographic features and clinicopathological characteristics of breast tumors at diagnosis and the associations between them, focusing on tumors with the worst prognosis. We analyzed cancers diagnosed in a cohort of 645,764 women aged 45–69 years participating in seven population-based screening programs in Spain, between January 1, 2000 and December 31, 2006 and followed up until June 2009. We included all interval cancers and a sample of screen-detected cancers, whether invasive or in situ. We compared tumor-related information and breast density for different phenotypes (Triple-negative (TN), HER2+, Luminal B and Luminal A) in screen-detected and interval cancers. We used Chi-square or Fisher’s exact test to compare major mammographic features of invasive versus in situ tumors, of screen-detected versus interval cancers, and of different types of interval cancers. We included 2582 tumors (1570 screen-detected and 1012 interval cancers). There were significant differences in the distribution of most clinicopathological variables between screen-detected and interval cancers. Invasive TN interval tumors were more common than other phenotypes in breasts with low mammographic density; three-quarters of these tumors presented as masses without associated calcifications. HER2+ tumors were more common in denser breasts and were associated with calcifications and multifocality. Architectural distortion was more common in Luminal A and Luminal B tumors. Certain radiologic findings are associated with pre-invasive lesions; these differ among invasive tumor phenotypes. We corroborate that TN and HER2+ cancers have distinctive appearances also in the context of population-based screening programs. This information can be useful for establishing protocols for diagnostic strategies in screening units.

引用

页码：403 / 415

页数：12

共 219 条

[11]

Borgquist S(2014)Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain Breast Cancer Res 16 R3-e72

[12]

Hartman L(1995)Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study J Natl Cancer Inst 87 670-43

[13]

Olsson A(2010)American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version) Arch Pathol Lab Med 134 e48-410

[14]

Jawdat F(2007)American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 18-1747

[15]

Zackrisson S(1991)Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 403-231

[16]

Eroles P(2011)Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Ann Oncol 22 1736-1852

[17]

Bosch A(2008)The mammographic appearance of breast carcinomas of invasive ductal type: relationship with clinicopathological parameters, biological features and prognosis Eur J Obstet Gynecol Reprod Biol 136 224-1037

[18]

Pérez-Fidalgo JA(2013)Breast cancer phenotype, nodal status and palpability may be useful in the detection of overdiagnosed screening-detected breast cancers Ann Oncol 24 1847-7

[19]

Lluch A(2015)Risk factors and tumor characteristics of interval cancers by mammographic density J Clin Oncol 33 1030-244

[20]

Elias SG(2013)In search of triple-negative DCIS: tumor-type dependent model of breast cancer progression from DCIS to the invasive cancer Tumour Biol 34 1-251

← 1 2 3 4 5 6 7 8 9 10 →